title: The therapeutic efficacy of edaravone in extensively burned rats.
abstract: BACKGROUND
  Extensive burn injury leads to production of free radicals subsequent to massive fluid resuscitation, which in turn increases the risk of acute lung injury. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, is clinically effective in improving the prognosis after cerebral infarction. However, the effect of edaravone against extensive burn injury has not been tested. Objected To evaluate whether edaravone can reduce free radical precursors in a 30% burn model in rats.
  
  
  METHODS
  Prospective, randomized controlled experiment.
  
  
  METHODS
  Animal basic science laboratory.
  
  
  METHODS
  Male Wistar rats weighing 200 to 220 g.
  
  
  METHODS
  All rats (n = 10) were given a 30% full-thickness burn according to the Walker and Mason method. Immediately after the burn, edaravone was injected into the rats (n = 5) intraperitoneally at a dose of 9 mg/kg. One hour after burn injury, blood and tissue samples were collected to analyze free radical changes of serum and tissue malondialdehyde (MDA) and xanthine oxidase (XOD) and lung white blood cells.
  
  
  RESULTS
  Statistical significance was found between nontreatment and edaravone treatment relative to serum MDA (mean +/- SD, 2.50 +/- 0.54 vs 1.74 +/- 0.29 nmol/mL), serum XOD (mean +/- SD, 5.04 +/- 1.67 vs 2.26 +/- 0.83 U/L), tissue MDA (mean +/- SD, 1268.7 +/- 289.9 vs 569.1 +/- 135.9 nmol/mg protein), tissue XOD (mean +/- SD, 256.3 +/- 58.1 vs 50.96 +/- 19.60 mU/g tissue), lung white blood cells (mean +/- SD, 3088 +/- 1144 vs 1542 +/- 575 mU/g tissue), and lung XOD (mean +/- SD, 428.3 +/- 210.5 vs 81.8 +/- 36.0 nmol/mg protein).
  
  
  CONCLUSIONS
  Edaravone treatment induces significant reduction of free radical precursors and their metabolites compared with controls in burn rats. This suggests that edaravone could be helpful in the clinical treatment of large burns.
authors.affiliation: Department of Emergency and Critical Care Medicine, Medical School of Kyorin University, Tokyo, Japan. take99051@hotmail.com
authors.forename: Takeo
authors.initials: T
authors.lastname: Koizumi
authors.forename: Hideharu
authors.initials: H
authors.lastname: Tanaka
authors.forename: Seiki
authors.initials: S
authors.lastname: Sakaki
authors.forename: Shuji
authors.initials: S
authors.lastname: Shimazaki
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002056:Burns / Q000188:drug therapy*; D004195:Disease Models, Animal; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use*; D005609:Free Radicals; D008168:Lung / Q000737:chemistry; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D011446:Prospective Studies; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014969:Xanthine Oxidase / Q000097:blood
chemical_list: D016166:Free Radical Scavengers; D005609:Free Radicals; D008315:Malondialdehyde; D014969:Xanthine Oxidase; D000077553:Edaravone; D000983:Antipyrine